Zymeworks ZYME
Zymeworks FY 2022: revenue $412.5M; diluted EPS $1.90
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001937653-23-000011
- Document
- 10-K
- Exhibit 4.1
- Warrants or notes
- Exhibit 10.59
- Material contract
- Exhibit 10.64
- Material contract
- Exhibit 10.74
- Material contract
Key figures from this report
These are the numbers Zymeworks reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$412.5MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income$124.3MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS$1.90No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$400.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$144.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Anaptysbio ANAB public float $633M, Dec 31, 2025
- Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
- ImmunityBio IBRX public float $690M, Jun 30, 2025
- Evoke Pharma EVOK
- Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old